改善病情抗风湿药对炎症性关节病患者全髋关节置换术结局的影响
一项基于全国理赔数据库的回顾性匹配队列研究纳入2009至2020年因类风湿关节炎、银屑病关节炎或幼年特发性关节炎行初次全髋关节置换术的患者26,867例,其中4,022例(15.0%)术前使用DMARD。结果显示,传统DMARD使用者2年结局未变差,而生物制剂DMARD使用者因感染性翻修导致2年假体生存率降低,假体周围感染率高于传统DMARD使用者(3.9%对2.1%,P=0.003)和对照组(3.9%对2.6%,P=0.007)。
要点
- 传统DMARD治疗与全髋置换术后2年不良结局无关。
- 生物制剂DMARD与因感染性翻修导致的2年假体生存率降低相关。
- 生物制剂使用者假体周围感染率高于传统DMARD使用者及对照组。
核心结论
- 传统DMARD治疗未与更差的2年结局相关,而生物制剂DMARD使用与因感染性翻修导致的2年假体生存率降低相关。
研究设计与样本
- DMARD使用者定义为术前90至360天内至少一次处方,按人口学、合并症和皮质类固醇使用进行1:1倾向评分匹配。
- 共识别26,867例患者,其中4,022例(15.0%)接受DMARD治疗。
主要发现
- DMARD使用者与对照组之间以及不同DMARD类型之间,2年无菌性翻修生存率无差异。
- 生物制剂DMARD使用者假体周围感染率高于传统DMARD使用者(3.9%对2.1%,P=0.003)。
- 生物制剂DMARD使用者假体周围感染率高于对照组(3.9%对2.6%,P=0.007)。
- 假体周围感染率升高主要由白细胞介素-6抑制剂(7.9%)和抗TNF药物(3.7%)使用者驱动。
关键数值与推荐
- DMARD使用者定义为术前90至360天内至少一次处方。
- 评估90天并发症率和2年假体生存率。
- 生物制剂DMARD使用者假体周围感染率为3.9%,传统DMARD使用者为2.1%(P=0.003),对照组为2.6%(P=0.007)。
- 白细胞介素-6抑制剂使用者假体周围感染率为7.9%,抗TNF药物使用者为3.7%。
临床怎么用
- 传统DMARD治疗未与更差的2年结局相关,生物制剂DMARD使用与因感染性翻修导致的2年假体生存率降低相关,提示需按指南进行围手术期协调管理。
- 强调骨科外科医生与风湿科医生协作的重要性。
局限性
- 观察到的关联是否由潜在免疫失调、特定DMARD效应或未测量混杂因素驱动,尚需进一步研究确定。
- 证据等级为III级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disease-modifying anti-rheumatic drugs (DMARDs) are essential in managing inflammatory arthritides such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis. As total hip arthroplasty (THA) and DMARD use become more common, it is unclear how DMARD use affects outcomes in this population. This study compared complications and implant survivorship after THA in patients who have inflammatory arthritis who had and did not have DMARD treatment. METHODS: A retrospective matched cohort study was performed using a national claims database. Patients who had rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis undergoing primary THA from January 1, 2009, to December 31, 2020, were included. The DMARD users were identified by at least one prescription within 90 to 360 days preoperatively. Propensity score matching (1:1) was done based on demographics, comorbidities, and corticosteroid use. The 90-day complication rates and 2-year implant survivorship were assessed. A total of 26,867 patients were identified, including 4,022 (15.0%) on DMARD therapy. RESULTS: Survivorship from aseptic revision did not vary at two years between DMARD users and controls or among DMARD types. When stratified by type, biologic DMARD users exhibited a higher rate of periprosthetic joint infection compared to both conventional DMARD users (3.9 versus 2.1%, P = 0.003) and controls (3.9 versus 2.6%; P = 0.007), which was predominantly driven by periprosthetic joint infection rates for those on interleukin-6 inhibitors (7.9%) and anti-TNF medications (3.7%). CONCLUSIONS: Conventional DMARD therapy was not associated with worse 2-year outcomes, while biologic DMARD use was associated with reduced 2-year implant survivorship due to septic revision. These findings underscore the importance of coordinated perioperative management in accordance with the guidelines regarding DMARD use and highlight the need for collaboration between orthopaedic surgeons and rheumatologists. Further investigation is needed to determine whether the observed associations are driven by underlying immune dysregulation, specific DMARD effects, or unmeasured confounding. LEVEL OF EVIDENCE: III.
引用
- Sheth ND, Ross BJ, Hrudka BT, et al. The Effects of Disease-Modifying Anti-Rheumatic Drugs on Total Hip Arthroplasty Outcomes in Patients Who Have Inflammatory Arthropathies. J Arthroplasty. 2026. PMID: 42001906. doi:10.1016/j.arth.2026.04.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。